{"id":391572,"date":"2014-08-22T00:00:00","date_gmt":"2014-08-22T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pforeu0114-biopharma-type-2-diabetes-the-dynamic-type-2-diabetes-landscape-market-access-levers-and-barriers-amid\/"},"modified":"2026-03-31T09:04:49","modified_gmt":"2026-03-31T09:04:49","slug":"pforeu0114-biopharma-type-2-diabetes-the-dynamic-type-2-diabetes-landscape-market-access-levers-and-barriers-amid","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pforeu0114-biopharma-type-2-diabetes-the-dynamic-type-2-diabetes-landscape-market-access-levers-and-barriers-amid\/","title":{"rendered":"Type 2 Diabetes (The Dynamic Type 2 Diabetes Landscape: Market Access Levers and Barriers amid Increasing Austerity in the EU5) | Physician &#038; Payer Forum | EU5 | 2014"},"content":{"rendered":"<p>The European type 2 diabetes market is contending with the convergence of innovative pharmaceutical offerings, such as Johnson &#038; Johnson\u2019s Invokana, AstraZeneca\u2019s Xigduo, and Takeda\u2019s Vipidia, and an increasingly cost-conscious reimbursement climate. The expanding treatment armamentarium could almost double the EU5 type 2 diabetes market by 2022. However, the German GBA (Joint Federal Committee of Physicians, Dentists, Hospitals, and Health Insurance Funds)\u2019s benefit assessment of novel diabetic agents is having ongoing consequences for novel drugs in Germany, and ripple effects are likely throughout Europe given the influence of German reference pricing on country-specific reimbursement policies.<\/p>\n","protected":false},"template":"","class_list":["post-391572","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-type-1-diabetes","biopharma-therapy-areas-type-2-diabetes","biopharma-geography-us","biopharma-date-574"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391572","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391572\/revisions"}],"predecessor-version":[{"id":577010,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391572\/revisions\/577010"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391572"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}